The next committee meeting date for the appraisal of blinatumomab for treating minimal residual B-precursor acute lymphoblastic leukaemia in remission has been rescheduled to allow the company (Amgen) additional time to provide new information requested by the committee in the ACD. The next committee meeting is now confirmed for 8 May 2019 (previously 3 April 2019).